Bladder Cancer Trials: A032103: MODERN:
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Breast Cancer Trials: A091901
Optimizing Endocrine Therapy Through Motivational Interviewing And Text Interventions
Breast Cancer Trials: EMBER-4 – J2J-MC-JZLH
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Breast Cancer Trials: CONCURxP : EAQ221CD
Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)
Breast Cancer Trials: A012103: OptimICE-PCR:
De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Breast Cancer Trials: The PREDICT Registry:
A Prospective Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast-Conserving Therapy
Lung Cancer Trials: M18-868 : Abbvie
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met+, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Lung Cancer Trials: NEOLA:
A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA).
Quality of Life Studies Trials: Cancer Genetic Syndromes Study:
A prospective survey of the patients’ understanding on genetic tests for cancer genetic syndromes
Quality of Life Studies Trials: FINTOX:
Prospective Longitudinal Assessment of Financial Burden Among Breast Cancer Patients.